HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field December 18, 2025 0 Novo Nordisk Files for FDA Approval of CagriSema, the First Once-Weekly Combination of GLP‑1 and Amylin Analogues for Weight Management December 18, 2025 0 Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors December 15, 2025 0 Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial Setmelanotide Demonstrating Positive Efficacy Signal in Prader-Willi Syndrome December 11, 2025 0